The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKK&#945; and overcomes gefitinib resistance in non-small cell lung cancer.

He, Ting; Gao, Yinglei; Fang, Yanfen; Zhang, Yangming; Zhang, Shuwei; Nan, Fajun; Ding, Jian; Chen, Yi

The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer.

He, Ting; Gao, Yinglei; Fang, Yanfen; Zhang, Yangming; Zhang, Shuwei; Nan, Fajun; Ding, Jian; Chen, Yi.

Afiliación

He T; Division of Anti-Tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Gao Y; University of Chinese Academy of Sciences, Beijing 100049, China.
Fang Y; Division of Anti-Tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Zhang Y; Division of Anti-Tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Zhang S; State Key Laboratory of Drug Research, the National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Nan F; University of Chinese Academy of Sciences, Beijing 100049, China.
Ding J; State Key Laboratory of Drug Research, the National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Chen Y; State Key Laboratory of Drug Research, the National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Cancer Biol Med ; 19(8)2022 02 22.

Article en En | MEDLINE | ID: mdl-35188360

Asunto(s)

Carcinoma de Pulmón de Células no Pequeñas; Neoplasias Pulmonares; Carcinoma de Pulmón de Células no Pequeñas/patología; Línea Celular Tumoral; Receptores ErbB/genética; Gefitinib/farmacología; Gefitinib/uso terapéutico; Inhibidores de Histona Desacetilasas/farmacología; Inhibidores de Histona Desacetilasas/uso terapéutico; Histona Desacetilasas/genética; Histona Desacetilasas/metabolismo; Histonas/uso terapéutico; Humanos; Quinasa I-kappa B/metabolismo; Quinasa I-kappa B/uso terapéutico; Neoplasias Pulmonares/patología; Factores de Transcripción/metabolismo; Factores de Transcripción/uso terapéutico

Palabras clave

HDAC inhibitor; IKKα; NSCLC; c-Met; gefitinib

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Biol Med Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google